"...both the company and its shareholders must begin to focus...

"...both the company and its shareholders must begin to focus their attention on more practical questions. Whether paxalisib works is no longer the primary consideration for investors. For now, that question has been answered to the best of our ability, and the answer is unambiguously positive.
We must now all address ourselves to the question of how paxalisib will be brought to market.
You will hear much from us in the year ahead about our plans and objectives in this area, as Kazia moves inexorably from a development-stage company to a profitable commercial organisation....."

I think for the chairman to be this direct is nothing but overwhelmingly positive in regard what we can expect moving forward. Well done management team - you set goals and timetables and without endless pump and dumps you have met your targets - what an absolute 180 degree from 2015 IMHO... if anyone need a reminder of that go observe over yonder...it feels like Novogen mk2 groundhog day IMHO..